Histopathology and molecular biology of ovarian epithelial tumors.
Histopathology and molecular biology of ovarian epithelial tumors.
复制标题
DOI：
10.1016/s1092-9134(98)80007-5
复制
发表时间：
1998-06-01
影响因子：
2
通讯作者：
Merino, M J
中科院分区：
文献类型：
--
作者：
Chuaqui, R F;Cole, K A;Merino, M J
卵巢的癌变表现出与该器官相关的特殊特征。首先，侵袭前甚至侵袭性病变很难发现，这解释了为什么大多数病例在晚期才被诊断出来。其次，低恶性潜能肿瘤（交界性肿瘤）仍然是卵巢病变的一个有争议的类别。最后，家族性卵巢肿瘤在分子水平上代表了一种有趣的致癌遗传模型。流式细胞术和免疫组化检测增殖标志物或癌基因为卵巢肿瘤患者的预后提供了重要的信息。分子数据，如特定遗传位点的杂合性缺失，也与预后相关。对多发性卵巢/盆腔病变患者进行克隆性研究，分析X染色体失活模式和基因缺失或突变，有助于了解这些病变的起源。研究基因表达模式的新技术，如cDNA文库构建和DNA微阵列技术，正被应用于研究肿瘤进展的组织学阶段，如正常组织、侵袭前组织和肿瘤组织。我们希望这些研究能够提供重要的信息，不仅有助于更好地了解癌变过程，而且有助于评估单个肿瘤的生物学和行为，确定患者预后，并最终影响治疗。
Carcinogenesis in the ovary presents special features related to that organ. First, the preinvasive or even invasive lesions are difficult to detect, which explains why most cases are diagnosed at an advanced stage. Second, the group of tumors of low malignant potential (borderline tumors) are still a controversial category of ovarian lesions. Finally, familial ovarian tumors represent an interesting hereditary model of carcinogenesis at the molecular level. Flow cytometry and immunohistochemistry for proliferative markers or oncogenes provide important prognostic information in patients with ovarian tumors. Molecular data, such as loss of heterozygosity at specific genetic loci, also have been correlated with prognosis. Clonality studies in patients with multiple ovarian/pelvian lesions analyzing chromosome X inactivation patterns and genetic deletions or mutations have contributed to the understanding of the origin of these lesions. New technologies to study gene expression patterns, such as cDNA library construction and DNA microarray technologies, are being applied to study histologic phases of tumor progression, such as normal, preinvasive, and tumor tissues. It is hoped that these studies will contribute important information not only for a better understanding of the process of carcinogenesis, but also for assessing the biology and behavior of individual tumors, determining patient prognosis, and eventually influencing therapy.